Stephen V Liu and Jarushka Naidoo report early KROCUS trial results for fulzerasib plus cetuximab in first line KRAS G12C NSCLC with a 69 percent response rate and relatively low discontinuation from treatment related adverse events.
Results from KROCUS study @TheLancetOncol: first-line fulzerasib (KRAS G12C inhibitor) + cetuximab (anti-EGFR mAb) in KRAS G12C NSCLC (n=47). RR 69%, median treatment duration 10.1m, only 6% required discontinuation due to TRAE.
Ph Ib/II KROCUS trial: Fulzerasib+cetuximab in 1L KRAS-G12C+ NSCLC @TheLancetOncol
ORR 69%
Early signal of a ‘targeted therapy only’ combo, less tox than expected
This finding is one of many signals tracked across Healthcare. The live feed updates every few hours with new authority voices, debates, and emerging ideas.
← Back to Healthcare